Benitec grants license in Ambion settlement
Tuesday, 10 August, 2004
Benitec (ASX: BLT) has settled its patent infringement case against US company Ambion, giving the company a world-wide non-exclusive licence to make and sell DNA-directed RNAi products.
The suit, which was originally filed on March 22, 2004 in the US, was settled out of court. Details of the settlement and licence have not been released by the company.
The Ambion suit was first announced in March, along with two other lawsuits filed against Nucleonics and Genscript Corporation.
"We will continue to protect our issued RNAi patent estate whilst enabling the widest usage of this important technology for both research and commercial therapeutic purposes," said CEO John McKinley in a statement.
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
